专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005032481A2 QUINAZOLINE DERIVATIVES AS MEDICAMENTS 审中-公开
标题翻译：喹诺酮衍生物作为药物
公开(公告)号：WO2005032481A2
公开(公告)日：2005-04-14
申请号：PCT/US2004/032430
申请日：2004-09-30
申请人： SCIOS INC. , DUGAR, Sundeep , CHAKRAVARTY, Sarvajit , MURPHY, Alison , MCENROE, Glen , CONTE, Aurelia , PERUMATTAM, John, J.
发明人： DUGAR, Sundeep , CHAKRAVARTY, Sarvajit , MURPHY, Alison , MCENROE, Glen , CONTE, Aurelia , PERUMATTAM, John, J.
IPC分类号： A61K
CPC分类号： C07D471/04 , C07D475/10 , C07D487/04
摘要： Quinazoline derivatives have the formula (I) or the pharmaceutically acceptable salts thereof; wherein each of Z 5 , Z 6 , Z 7 and Z 8 is N or CH and wherein one or two Z 5 , Z 6 , Z 7 and Z 8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R 1 is independently OH, SH, NH 2 , OR, SR, NHR, halo or R-halide; wherein two adjacent R 1 groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R 2 is independently R, halo, R-halide, OR-halide, NH 2 , CONH 2 or CONHR; wherein R is optionally substituted C 1 -C 12 alkyl, C 1 -C 12 alkenyl, C 1 -C 12 alkynyl, or aryl C 1 -C 12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are =O, =N, or OH; and wherein R 3 is H or CH 3 . Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGFβ activity.
摘要翻译：喹唑啉衍生物具有式（I）或其药学上可接受的盐; 其中Z 5，Z 6，Z 7和Z 8中的每一个是N或CH，并且其中一个或两个Z 5，Z 6，Z 7和Z 8，是N，其中两个相邻的Z位置不能是N; 其中m和n各自独立地为0-3; 其中R 1独立地是OH，SH，NH 2，OR，SR，NHR，卤素或R卤化物; 其中两个相邻的R 1基团可以连接形成5-6个成员的脂族杂环; 其中R 2独立地是R，卤素，卤化物，或者卤化物，NH 2，CONH 2或CONHR; 其中R是任选取代的C 1 -C 12烷基，C 1 -C 12链烯基，C 1 -C 12炔基或芳基C 1 -C 12烷基，其含有0-4个杂原子代替碳主链中的碳，其中任选取代基为= = N或OH; 并且其中R 3是H或CH 3。这样的化合物可用于治疗以增强的TGFbeta活性为特征的病症的药物组合物和方法。

2. 发明申请

WO2006112828A1 AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE 审中-公开
标题翻译：作为P38激酶的抑制剂的氨基衍生物
公开(公告)号：WO2006112828A1
公开(公告)日：2006-10-26
申请号：PCT/US2005/012969
申请日：2005-04-15
申请人： SCIOS, INC. , DUGAR, Sundeep , GOYAL, Bindu , LU, Qing , LUEDTKE, Gregroy, R. , MAVUNKEL, Babu, J. , NASHASHIBI, Imad , PERUMATTAM, John, J. , TAN, Xuefei , TESTER, Richland , WANG, Dan, Xiong
发明人： DUGAR, Sundeep , GOYAL, Bindu , LU, Qing , LUEDTKE, Gregroy, R. , MAVUNKEL, Babu, J. , NASHASHIBI, Imad , PERUMATTAM, John, J. , TAN, Xuefei , TESTER, Richland , WANG, Dan, Xiong
IPC分类号： A61K31/496 , A61K31/437 , C07D471/04
CPC分类号： C07D471/04 , C07D487/04
摘要： The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through an azacyclic linker to another cyclic moiety.
摘要翻译：本发明涉及使用作为氮杂吲哚的化合物抑制p38激酶，优选p38-a的方法，其中所述氮杂吲哚通过氮杂环链接体与另一个环状部分偶联。

3. 发明申请

WO0012497B1 QUINAZOLINE DERIVATIVES AS MEDICAMENTS 审中-公开
公开(公告)号：WO0012497B1
公开(公告)日：2000-09-08
申请号：PCT/US9919846
申请日：1999-08-27
申请人： SCIOS INC , CHAKRAVARTY SARVAJIT , DUGAR SUNDEEP , PERUMATTAM JOHN J , SCHREINER GEORGE F , LIU DAVID Y , LEWICKI JOHN A
发明人： CHAKRAVARTY SARVAJIT , DUGAR SUNDEEP , PERUMATTAM JOHN J , SCHREINER GEORGE F , LIU DAVID Y , LEWICKI JOHN A
IPC分类号： A61K31/517 , A61K31/519 , A61K31/5355 , A61K39/395 , A61P1/16 , A61P1/18 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/12 , A61P17/02 , A61P19/02 , A61P29/00 , A61P43/00 , C07D239/94 , C07D401/04 , C07D401/12 , C07D403/12 , C07D471/04 , C07D487/02 , C07D239/91 , A61K31/47 , A61K31/505 , C07D215/00 , C07D239/72
CPC分类号： C07D401/12 , A61K31/519 , C07D239/94 , C07D471/04
摘要： The invention is directed to methods to inhibit TGF- beta and/or p38- alpha kinase using compounds of formula (1) or the pharmaceutically acceptable salts thereof wherein R is a noninterfering substituent; each Z is CR or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

4. 发明申请

WO2005032481A3 QUINAZOLINE DERIVATIVES AS MEDICAMENTS 审中-公开
标题翻译：喹唑啉衍生物作为药物
公开(公告)号：WO2005032481A3
公开(公告)日：2005-06-16
申请号：PCT/US2004032430
申请日：2004-09-30
申请人： SCIOS INC , DUGAR SUNDEEP , CHAKRAVARTY SARVAJIT , MURPHY ALISON , MCENROE GLEN , CONTE AURELIA , PERUMATTAM JOHN J
发明人： DUGAR SUNDEEP , CHAKRAVARTY SARVAJIT , MURPHY ALISON , MCENROE GLEN , CONTE AURELIA , PERUMATTAM JOHN J
IPC分类号： A61K20060101 , A61K31/4965 , A61K31/517 , A61K31/519 , C07D471/04 , C07D475/10 , C07D487/04
CPC分类号： C07D471/04 , C07D475/10 , C07D487/04
摘要： Quinazoline derivatives have the formula (I) or the pharmaceutically acceptable salts thereof; wherein each of Z , Z , Z and Z is N or CH and wherein one or two Z , Z , Z and Z are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl, or aryl C1-C12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are =O, =N, or OH; and wherein R is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGFbeta activity.
摘要翻译：喹唑啉衍生物具有式（I）或其药学上可接受的盐; 其中Z 5，Z 6，Z 7和Z 8中的每一个是N或CH，并且其中一个或两个Z 5，Z 6，Z 7和Z 8独立地选自氢，是N并且其中两个相邻的Z位置不能是N; 其中m和n各自独立地为0-3; 其中R 1独立地为OH，SH，NH 2，OR，SR，NHR，卤素或R-卤化物; 其中两个相邻的R 1基团可以连接形成5-6元的脂族杂环; 其中R 2独立地为R，卤素，R-卤化物，OR-卤化物，NH 2，CONH 2或CONHR; 其中R是任选取代的C 1 -C 12烷基，C 1 -C 12烯基，C 1 -C 12炔基或芳基C 1 -C 12烷基，在碳骨架中含有0-4个杂原子代替碳，其中任选取代基为= O， = N或OH; 并且其中R 3是H或CH 3。此类化合物可用于治疗以增强的TGFβ活性为特征的病症的药物组合物和方法。

5. 发明申请

WO0012497A3 QUINAZOLINE DERIVATIVES AS MEDICAMENTS 审中-公开
标题翻译：喹唑啉衍生物作为药物
公开(公告)号：WO0012497A3
公开(公告)日：2000-06-29
申请号：PCT/US9919846
申请日：1999-08-27
申请人： SCIOS INC , CHAKRAVARTY SARVAJIT , DUGAR SUNDEEP , PERUMATTAM JOHN J , SCHREINER GEORGE F , LIU DAVID Y , LEWICKI JOHN A
发明人： CHAKRAVARTY SARVAJIT , DUGAR SUNDEEP , PERUMATTAM JOHN J , SCHREINER GEORGE F , LIU DAVID Y , LEWICKI JOHN A
IPC分类号： A61K31/517 , A61K31/519 , A61K31/5355 , A61K39/395 , A61P1/16 , A61P1/18 , A61P7/00 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/12 , A61P17/02 , A61P19/02 , A61P29/00 , A61P43/00 , C07D239/94 , C07D401/04 , C07D401/12 , C07D403/12 , C07D471/04 , C07D487/02 , C07D239/91 , A61K31/47 , A61K31/505 , C07D215/00 , C07D239/72
CPC分类号： C07D401/12 , A61K31/519 , C07D239/94 , C07D471/04
摘要： The invention is directed to methods to inhibit TGF- beta and/or p38- alpha kinase using compounds of formula (1) or the pharmaceutically acceptable salts thereof wherein R is a noninterfering substituent; each Z is CR or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar' is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
摘要翻译：本发明涉及使用式（1）化合物或其药学上可接受的盐抑制TGF-β和/或p38-α激酶的方法，其中R 3是非干扰性取代基; 每个Z是CR 2或N，其中环A中不超过两个Z位置是N，并且其中环A中的两个相邻Z位置不能是N; 每个R 2独立地为非干扰取代基; L是一个链接器; n是0或1; Ar'是任选被1-3个非干扰性取代基取代的环脂族，环状杂脂族，芳族或杂芳族部分的残基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式